Hematologic Oncology | Specialty

The OncLive Hematology Oncology condition center page is a comprehensive resource for clinical news and expert insights on various hematologic malignancies, including leukemias, lymphomas, myeloproliferative neoplasms, multiple myeloma, and much more. This section features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in hematologic cancers.

Dr. Palmer on the Treatment Landscape of aGVHD

August 4th 2020

Jeanne M. Palmer, MD, discusses the current treatment landscape of acute graft-versus-host disease.

FDA Grants Aspacytarabine Fast Track Status for Older Patients With AML

August 4th 2020

The FDA has granted a fast track designation for aspacytarabine as treatment for acute myeloid leukemia in adults aged 75 years or older who have comorbidities that preclude the utilization of intensive induction chemotherapy.

Non-Steroid Treatments Lead Progress in GVHD Management

August 4th 2020

Jeanne M. Palmer, MD, discusses advances made with non-steroid treatments in graft-versus-host disease and how biomarkers such as ST2 and REG-3 alpha might help to inform future treatment decisions.

Tisagenlecleucel Shows Clinically Meaningful Benefit in Relapsed/Refractory Follicular Lymphoma

August 4th 2020

Tisagenlecleucel was found to elicit clinically meaningful activity in patients with relapsed/refractory follicular lymphoma, meeting the phase 2 ELARA trial’s primary end point of complete response rate.

Dr. Palmer on Complications of Acute Graft-Versus-Host Disease

August 3rd 2020

Jeanne M. Palmer, MD, discusses common complications associated with acute graft-versus-host disease.

FDA Approves Tafasitamab Plus Lenalidomide in Relapsed/Refractory DLBCL

August 1st 2020

The FDA has approved tafasitamab-cxix (Monjuvi) in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant.

Dose-Adjusted Chemo Regimen Shows Efficacy in Burkitt Lymphoma, Regardless of Age or HIV Status

July 31st 2020

Findings from an ongoing, multicenter, phase 2 study identified an alternative treatment to dose intense chemotherapy through dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab for adults with untreated Burkitt lymphoma and diffuse large B-cell lymphoma.

Dr. Shaughnessy on the Promise of CAR T-Cell Therapy in Hematologic Malignancies

July 30th 2020

Paul J. Shaughnessy, MD, discusses the promising future of CAR T-cell therapy in relapsed/refractory hematologic malignancies.

DiNardo Discusses VIALE-A and Venetoclax Combo in AML

July 30th 2020

In our exclusive interview, Courtney DiNardo, MD, MSCE, discusses the role of venetoclax in acute myeloid leukemia and explains the significance of the results of the VIALE-A trial.

Future Directions in CLL

July 30th 2020

Novel Therapies for CLL

July 30th 2020

PI3 Kinase Inhibitors in CLL

July 30th 2020

Therapeutic Sequencing in CLL

July 30th 2020

BTK Inhibitors in Relapsed/Refractory CLL

July 30th 2020

MURANO Trial Update in R/R CLL

July 30th 2020

Utility of MRD Testing in CLL Management

July 30th 2020

Venetoclax Combinations, Safety and Efficacy

July 30th 2020

Venetoclax and Obinutuzumab in CLL

July 30th 2020

Novel Therapies for Relapsed/Refractory CLL

July 30th 2020

Relapsed/Refractory CLL: Treatment Selection

July 30th 2020